Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The US FDA is recommending against co-administration of boceprevir [Victrelis] and certain ritonavir-boosted HIV protease inhibitors.

    • 13 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      FDA.FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs. Internet Document: 26 Apr 2012. Available from: URL: http://www.fda.gov

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    The US FDA is recommending against co-administration of boceprevir [Victrelis] and certain ritonavir-boosted HIV protease inhibitors.. React. Wkly. 1400, 2 (2012). https://doi.org/10.2165/00128415-201214000-00005

    Download citation

    Keywords

    • Public Health
    • Hepatitis
    • Protease Inhibitor
    • Health Professional
    • Treatment Response